Lexicon Pharmaceuticals (LXRX) Income towards Parent Company (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Income towards Parent Company for 17 consecutive years, with -$5.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 81.51% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at -$43.0 million (up 77.51% YoY), while the FY2025 annual figure was -$60.6 million, up 90.2% from the prior year.
• Income towards Parent Company rose to -$5.3 million in Q1 2026 per LXRX's latest filing, from -$16.8 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$4.2 million in Q2 2025 and bottomed at -$68.3 million in Q3 2024.
• Historically, Income towards Parent Company has averaged -$34.2 million across 5 years, with a median of -$28.6 million in 2025.
• Annual changes were most pronounced in 2023 — Income towards Parent Company sank 146.74% — and 2025, when it jumped 92.75%.
• Lexicon Pharmaceuticals' Income towards Parent Company stood at -$25.7 million in 2022, then sank by 106.2% to -$53.1 million in 2023, then surged by 31.05% to -$36.6 million in 2024, then jumped by 54.06% to -$16.8 million in 2025, then jumped by 68.5% to -$5.3 million in 2026.
• Business Quant data shows LXRX's Income towards Parent Company at -$5.3 million in Q1 2026, -$16.8 million in Q4 2025, and -$16.7 million in Q3 2025.